In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

Acceleron To Be Next M&A Target With Rumored $11bn Deal

The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.

Another Activist Investor Joins Calls For GSK Leadership Review

A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO, and has underlined competitive threats to a key pipeline candidate.

Companies Commercial

Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech

The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.

Dermatology Immune Disorders

AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal

VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.

Companies Research & Development

New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.

Commercial Companies

ESMO: Regeneron Mounts Credible Challenge To Keytruda With Libtayo Survival Data In NSCLC

Libtayo looks to have surpassed all competitors but Merck’s Keytruda in first line NSCLC, but the unique ‘all-comers’ trial design of EMPOWER-Lung-3 complicates the picture.

Commercial Companies
See All
UsernamePublicRestriction

Register